news
Diabetes drugs aid macrophages to control inflammation
Dr Lazar’s team identified that TZDs, while working for PPAR gamma, promoted the metabolism of glutamine, an amino acid...
List view / Grid view
obesity
news
Metabocin shows promise as a potent anti-obesity treatment
A novel drug based on capsaicin caused long-term weight loss and improved metabolic health in mice eating a high-fat diet...
news
Semaglutide may help people with obesity lose weight
A compound that mimics a naturally occurring hormone that regulates appetite may help people who have obesity but not diabetes to lose weight...
news
Prescription labels provide insufficient dosing guidance for obese children
Despite providing incentives to drug manufacturers to encourage the study of medications in children, few approved drugs include safe dosing information for obese children...
news
Mindfulness-based therapy may reduce stress in obese patients
In a randomised clinical trial of women who were overweight or obese, mindfulness-based stress reduction (MBSR) increased mindfulness and decreased stress compared with health education.
news
Nutrition, the microbiome, and Autism Spectrum Disorder: A review
Over the last decade, research has revealed more about the human gut microbiome—the environment within the gastrointestinal tract—where microbes, especially bacteria, reside.
article
O is for Obesity
2 December 2016 | By Niamh Louise Marriott, Digital Editor
O is for Obesity - the next instalment of our daily pharmaceutical alphabet bringing you up to date with all the latest research...
news
Gelesis appoints new Chief Operating Officer in anticipation of obesity product launch
6 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Gelesis, a biotechnology company focused on developing products to safely induce weight loss and improve glycaemic control, have appointed David Pass, PhD as Chief Operating Officer...
news
Early response to Saxenda results in improvement in weight loss
3 June 2016 | By Victoria White, Digital Content Producer
Three-year data show early response to Novo Nordisk’s Saxenda (liraglutide 3 mg) resulted in improvements in weight loss and cardiometabolic risk factors...
